Showing results (191-200 of 219) with videos related to

Sort By:
Pageof 22
Neuro-Oncology|September 11, 2021
A molecularly integrated grade for meningiomaJoseph Driver, Samantha E Hoffman, Sherwin Tavakol, et al.
Nature Genetics|October 11, 2016
The genomic landscape of schwannomaSameer Agnihotri, Shahrzad Jalali, Mark R Wilson, et al.
Neuro-Oncology|June 14, 2019
Automatic assessment of glioma burden: a deep learning algorithm for fully automated volumetric and bidimensional measurementKen Chang, Andrew L Beers, Harrison X Bai, et al.
Neuro-Oncology|May 20, 2021
Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial resultsWenya Linda Bi, Lakshmi Nayak, David M Meredith, et al.
Neuro-Oncology|December 26, 2024
The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant gliomaMacarena I de la Fuente, Mehdi Touat, Martin J van den Bent, et al.
Neuro-Oncology|July 31, 2024
A comparative analysis of IDH-mutant glioma in pediatric, young adult, and older adult patientsMary Jane Lim-Fat, Jennifer A Cotter, Mehdi Touat, et al.
Neuro-Oncology|May 29, 2025
Clinical, molecular, and radiological predictors of prognosis in newly diagnosed astrocytoma, IDH-mutant, WHO grade 4Aleksandra B Lasica, Zhou Lan, Julie J Miller, et al.
Neuro-Oncology|August 20, 2024
Contemporary prognostic signatures and refined risk stratification of gliomas: An analysis of 4400 tumorsHia S Ghosh, Ruchit V Patel, Eleanor Woodward, et al.
Nature Communications|May 19, 2022
Target receptor identification and subsequent treatment of resected brain tumors with encapsulated and engineered allogeneic stem cellsDeepak Bhere, Sung Hugh Choi, Pim van de Donk, et al.
Neuro-Oncology Advances|February 6, 2025
Ivosidenib for the treatment of IDH1-mutant glioma, grades 2-4: Tolerability, predictors of response, and outcomesTyler A Lanman, Gilbert Youssef, Raymond Huang, et al.
Pageof 22